OncoZenge Releases Paper on BupiZenge™ Addressing Unmet Medical Needs
Stockholm, Sweden – April 25 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces the release of a report outlining the opportunity to address critical Unmet Medical Needs in oncology care.
Pain remains one of the leading reasons for cancer treatment interuptions and significantly impacts Quality of Life during chemotherapy and radiotherapy. BupiZenge™ is uniquely positioned to help millions of patients, alleviating their oral pain stemming from oral mucositis, a common and debilitating side effect of cancer treatments.
OncoZenge is pleased to offer this report outlining the Unmet Medical Needs in treating oral mucositis pain in oncology care, including an overview of the current treatment regimens and patients' Quality of Life challenges. The report has been developed internally at OncoZenge with the assistance of members of OncoZenge's Advisory Board.
Stian Kildal, CEO of OncoZenge comments, “As part of our efforts to increase awareness and transparency on the opportunity ahead of us, we are pleased to offer this report on the disease, current Standard of Care and the research background to our conviction BupiZenge has the potential to be established as first line treatment for our chosen indication of treating oral mucositis pain in cancer care.”
Download the report from this press release or by visiting: https://oncozenge.se/wp-content/uploads/2024/04/Report-The-Case-for-BupiZenge.pdf
BupiZenge™ - Potential to be the leading treatment for oral pain.
For additional information, please contact:
Stian Kildal, CEO, mobile: +46 76 115 3797, e-mail: [email protected]
Certified Adviser
OncoZenge’s Certified Adviser is Carnegie Investment Bank AB (publ).
OncoZenge AB
Gustavslundsvägen 34, 167 51 Stockholm, Sweden
About OncoZenge
OncoZenge develops a novel, effective, safe and well-tolerated treatment for oral pain in conditions where currently available treatment options either do not achieve sufficient pain relief or are associated with significant side effects. BupiZenge™ is a new oral lozenge formulation of bupivacaine, an anaesthetic with decades of clinical experience. OncoZenge's lead indication is oral pain due to an inflammatory condition called oral mucositis that affects millions of patients receiving cancer treatment. Oral mucositis causes profound physical and psychological suffering, and is a large unmet medical need for an effective, opioid-sparing treatment option. BupiZenge™ has shown significantly better pain relief compared to standard of care in this indication in a Phase 2 trial.
OncoZenge has its headquarters in Stockholm, Sweden, and its share is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ.